Source: Virchous Archiv. Conference titles: European Congress of Pathology. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TIEZZI, Daniel Guimarães et al. HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. Heidelberg: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2005APA
Tiezzi, D. G., Andrade, J. M. de, Ribeiro-Silva, A., Tiezzi, M. G., Marana, H. R. C., Zola, F. E., & Sarmento-Filho, J. M. (2005). HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. Heidelberg: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Tiezzi DG, Andrade JM de, Ribeiro-Silva A, Tiezzi MG, Marana HRC, Zola FE, Sarmento-Filho JM. HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. 2005 ; 447( 2): 364.[citado 2024 nov. 01 ]Vancouver
Tiezzi DG, Andrade JM de, Ribeiro-Silva A, Tiezzi MG, Marana HRC, Zola FE, Sarmento-Filho JM. HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. 2005 ; 447( 2): 364.[citado 2024 nov. 01 ]
